Hasil Pencarian - Xingsheng Hu

Perbaiki Hasil
  1. 1
    The expression and role of SUZ12 in lung adenocarcinoma

    The expression and role of SUZ12 in lung adenocarcinoma oleh Xingsheng Hu, Chunhong Hu, Ping Zhong

    Diterbitkan 2024-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    A re-irradiation dose of 55–60 Gy improves the survival rate of patients with local recurrent esophageal squamous cell carcinoma after radiotherapy

    A re-irradiation dose of 55–60 Gy improves the survival rate of patients with local recurrent esophageal squamous cell carcinoma after radiotherapy oleh Xun Wu, Xingsheng Hu, Junru Chen, Lang He

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Utility of NSE, ProGRP and LDH in Diagnosis and Treatment
in Patients with Small Cell Lung Cancer

    Utility of NSE, ProGRP and LDH in Diagnosis and Treatment
in Patients with Small Cell Lung Cancer oleh Yan PENG, Yan WANG, Junling LI, Xuezhi HAO, Xingsheng HU

    Diterbitkan 2016-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Prognostic Value of MACC1 and c-met Expressions in Non-small Cell Lung Cancer

    Prognostic Value of MACC1 and c-met Expressions in Non-small Cell Lung Cancer oleh Xingsheng HU, Xi FU, Shimin WEN, Xinyi ZOU, Yusong LIU

    Diterbitkan 2012-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Recombinant Human Endostatin in the Treatment of Advanced Lung Squamous Cell Carcinoma

    Recombinant Human Endostatin in the Treatment of Advanced Lung Squamous Cell Carcinoma oleh Puyuan XING, Xuezhi HAO, Xingsheng HU, Yan WANG, Junling LI

    Diterbitkan 2016-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC)

    Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small ce... oleh Ziyi Xu, Teng Li, Xingsheng Hu, Xuezhi Hao, Puyuan Xing, Junling Li

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study

    The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study oleh Yu Feng, Liling Huang, Haohua Zhu, Le Tang, Xingsheng Hu, Yuankai Shi

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Is IMRT Superior or Inferior to 3DCRT in Radiotherapy for NSCLC? A Meta-Analysis.

    Is IMRT Superior or Inferior to 3DCRT in Radiotherapy for NSCLC? A Meta-Analysis. oleh Xingsheng Hu, Wenwu He, Shimin Wen, Xuqin Feng, Xi Fu, Yusong Liu, Ke Pu

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance

    Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance oleh Mingzhao Wang, Jun Zhao, Tong Chen, Xingsheng Hu, Lin Wang, Yuankai Shi, Yutao Liu

    Diterbitkan 2023-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China

    Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China oleh Xingsheng Hu, Chunhong Hu, Dixuan Jiang, Qian Zuo, Ya Li, Yang Wang, Xiangyu Chen

    Diterbitkan 2020-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Preparation of double-layered Co−Ci/NiFeOOH co-catalyst for highly meliorated PEC performance in water splitting

    Preparation of double-layered Co−Ci/NiFeOOH co-catalyst for highly meliorated PEC performance in water splitting oleh Xingsheng Hu, Yan Li, Xinxin Wei, Lei Wang, Houde She, Jingwei Huang, Qizhao Wang

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Clinical characteristics and risk factors for severity of COVID-19 outside Wuhan: a double-center retrospective cohort study of 213 cases in Hunan, China

    Clinical characteristics and risk factors for severity of COVID-19 outside Wuhan: a double-center retrospective cohort study of 213 cases in Hunan, China oleh Xingsheng Hu, Chunhong Hu, Yong Yang, Juan Chen, Ping Zhong, Yajing Wen, Xiangyu Chen

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

    Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. oleh Xingsheng Hu, Ke Pu, Xuqin Feng, Shimin Wen, Xi Fu, Cuihua Guo, Wenwu He

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China

    Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China oleh Xingsheng Hu, Chunhong Hu, Ping Zhong, Yajing Wen, Yong Yang, Juan Chen, Xiangyu Chen

    Diterbitkan 2020-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis

    Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis oleh Yu Feng, Yunxia Tao, Haizhu Chen, Yu Zhou, Le Tang, Chenwei Liu, Xingsheng Hu, Yuankai Shi

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations

    Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations oleh Teng Li, Shouzheng Wang, Jianming Ying, Yan Wang, Xingsheng Hu, Xuezhi Hao, Ziyi Xu, Puyuan Xing, Junling Li

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    A Retrospective Study of the Efficacy and Toxicity of Irinotecan in Combination with Nedaplatin versus Irinotecan in Combination with Cisplatin as Salvage
Treatment in Refractory or Relapsed Small Cell Lung Cancer

    A Retrospective Study of the Efficacy and Toxicity of Irinotecan in Combination with Nedaplatin versus Irinotecan in Combination with Cisplatin as Salvage
Treatment in Refractory o... oleh Shufei YU, Yan WANG, Xingsheng HU, Hongyu WANG, Xuezhi HAO, Jianping XU, Junling LI, Xiangru ZHANG, Yuankai SHI

    Diterbitkan 2013-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma

    Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma oleh Shouzheng Wang, Tongji Xie, Xuezhi Hao, Yan Wang, Xingsheng Hu, Lin Wang, Yan Li, Junling Li, Puyuan Xing

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Efficacy of Gefitinib for Young Patients with Unknown EGFR Gene Mutation 
in Advanced Lung Adenocarcinoma

    Efficacy of Gefitinib for Young Patients with Unknown EGFR Gene Mutation 
in Advanced Lung Adenocarcinoma oleh Yutao LIU, Yuankai SHI, Xingsheng HU, Xuezhi HAO, Junling LI, Ziping WANG, Yan WANG, Hongyu WANG, Xiangru ZHANG, Yan SUN

    Diterbitkan 2014-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer

    First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer oleh Xingsheng Hu, Xin Zheng, Sheng Yang, Lin Wang, Xuezhi Hao, Xinge Cui, Lieming Ding, Li Mao, Pei Hu, Yuankai Shi

    Diterbitkan 2020-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: